Innate Pharma S.A. (EPA:IPH)
1.936
+0.036 (1.89%)
Aug 14, 2025, 12:38 PM CET
Innate Pharma Revenue
In the year 2024, Innate Pharma had annual revenue of 20.12M EUR, down -67.36%. Innate Pharma had revenue of 7.78M in the half year ending December 31, 2024, a decrease of -35.66%.
Revenue
20.12M
Revenue Growth
-67.36%
P/S Ratio
8.70
Revenue / Employee
111.17K
Employees
181
Market Cap
175.12M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 20.12M | -41.52M | -67.36% |
Dec 31, 2023 | 61.64M | 3.97M | 6.88% |
Dec 31, 2022 | 57.67M | 32.97M | 133.47% |
Dec 31, 2021 | 24.70M | -45.07M | -64.60% |
Dec 31, 2020 | 69.77M | -15.68M | -18.35% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
EssilorLuxottica Société anonyme | 27.24B |
Sanofi | 45.74B |
Sartorius Stedim Biotech | 2.90B |
bioMérieux | 3.98B |
Eurofins Scientific SE | 7.14B |
Ipsen | 3.76B |
ABIVAX Société Anonyme | 10.59M |
Virbac | 1.40B |
Innate Pharma News
- 16 days ago - Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference - Business Wire
- 2 months ago - Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences - Business Wire
- 2 months ago - Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress - Business Wire
- 2 months ago - Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences - Business Wire
- 2 months ago - Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides - Business Wire
- 2 months ago - Outcome of Innate Pharma's 2025 Annual General Meeting - Business Wire
- 3 months ago - Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting - Business Wire
- 3 months ago - Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress - Business Wire